« Go Back

Senior Scientist, In Vitro Biology

Summary
The Biology group at Pipeline Therapeutics is currently seeking a Senior Scientist to join our research team in San Diego. The successful candidate will play a key role in our small molecule drug discovery effort focusing on neuro-regenerative therapies. This is a lab-based position and responsibilities will include designing, managing, and executing in vitro assays to drive our drug discovery programs. The successful candidate will be able to investigate literature and propose new directions for the team to pursue.


Key Responsibilities
Conduct in vitro assays within the Biology team from primary in vitro screens through mechanistic query of disease relevant biology. This will include working with the research team to identify and implement new assays systems, as well as providing scientific input into cross-functional areas. Provide timely presentations of research rationale, key data, issues, and accomplishments to members of the discovery team and to the broader organization. Maintain a research environment that is safe and conducive to the open sharing of ideas and responsibilities. The candidate will also manage and analyze experimental data, write and submit papers to scientific journals, write reports for regulatory submission, and present experimental results at scientific conferences.


Qualifications

Education
PhD or equivalent in Neuroscience, Molecular or Cellular Biology, or related disciplines with 2+ years of experience in the biotech or pharmaceutical industry or equivalent postdoctoral work.

Experience
4-10 years’ experience in industry is preferred. 2+ years in drug discovery and neurodegenerative disease areas is highly desired. Demonstrated success in identifying and establishing screening assays (HTS not required). Experience with primary neurons or tissue models. Proficiency in laboratory bench skills such as RNA analysis, enzyme assays, kinetic analyses, microscopy, and/or quantitative histology is desired. Experience with ex vivo or in vivo brain or spinal cord systems, or human IPSCs is a bonus. Familiarity with quantitative small molecule drug discovery, statistical analysis, and biomarker discovery. Strong communication skills including generating slide decks and presentation.

Attributes
Strong experimental background and experience in hypothesis-driven biological/translational research with a demonstrated ability to execute well-designed, creative experiments. Must be a highly flexible, results oriented, independent self-starter who enjoys working in a fast-paced and dynamic, team-oriented environment. Collaborative and have excellent communication and interpersonal skills. Can prioritize multiple high priority tasks effectively. Ability to integrate complex scientific ideas, generate testable hypotheses, and execute broad understanding of drug discovery and development in pre-clinical development. Strong problem-solving skills with a high level of creativity and productivity.

Pipeline Therapeutics offers an excellent compensation and benefits package. Please submit your resume or CV and supporting documents to info@pipeline-tx.com.

« Go Back

Pipeline Therapeutics to Present Multiple Posters at SFN 2022 Neuroscience Annual Meeting

SAN DIEGO, November 8, 2022 – Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that it will present two posters at the SFN 2022 Neuroscience Annual Meeting, taking place November 12-16, 2022, in San Diego, CA. 

Poster Presentation Details:

Title:Discovery of remyelination therapeutics that overcome the effects of inflammatory macrophages on oligodendrocyte formation

Poster Number: 194.11

Session Title:  Mechanisms and Therapeutics of Demyelinating and Peripheral Nerve Disorders

Date/Time: November 13, 2022, 1:00 PM – 5:00 PM

Title:PIPE-791, a potent brain-penetrant selective LPA1 antagonist, reduces neuroinflammation in vivo

Poster Number: 377.27

Session Title:  Mechanisms of Neurodegeneration and Neuroprotective Therapies

Date/Time: November 14, 2022, 1:00 PM – 5:00 PM

More information can be found on the meeting website at SFN Meeting 2022 | 12-16 Nov 2022 | San Diego, USA

About Pipeline Therapeutics
Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair.  The Company has a broad pipeline of programs to address multiple CNS disorders. Its flagship program, PIPE-307, has completed two Phase 1 clinical trials – a SAD/MAD study and a PET study – in healthy volunteers, and has received Investigational New Drug clearance from the Food and Drug Administration to initiate clinical development in relapsing-remitting MS patients.  

For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com

« Go Back

Pipeline Therapeutics Announces Participation in Upcoming Investor Conferences in November

SAN DIEGO, November 1, 2022 – Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that management will present at the following investor conferences during November 2022:

  • Guggenheim 4th Annual Immunology and Neurology Day, November 14-15, in New York, NY
  • Stifel Healthcare Conference, November 15-16, in New York, NY

About Pipeline Therapeutics
Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair.  The Company has a broad pipeline of programs to address multiple CNS disorders. Its flagship program, PIPE-307, has completed two Phase 1 clinical trials – a SAD/MAD study and a PET study – in healthy volunteers, and has received Investigational New Drug clearance from the Food and Drug Administration to initiate clinical development in relapsing-remitting MS patients.  

For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com

« Go Back

Pipeline Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

SAN DIEGO, May 25/26, 2022 – Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that company management will present at the Jefferies Global Healthcare Conference taking place June 8-10, 2022 in New York, NY.  Carmine Stengone, Pipeline’s President and CEO, will present a company overview on Thursday, June 9, 2022 at 10:00 am ET.  Company management will also participate in one-on-one meetings with investors during the conference.

About Pipeline Therapeutics
Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair.  The Company has a broad pipeline of programs to address CNS and neuro-otology conditions. Its flagship program, PIPE-307, has completed a Phase 1 clinical trial in healthy volunteers and has received IND clearance from the FDA to initiate a Phase 1b/2a trial in relapsing-remitting MS patients.  For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com

« Go Back

Pipeline Therapeutics to Present at Multiple Investor Conferences in May 2022

SAN DIEGO, May 5, 2022 – Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that company management will present at the following investor conferences:

  • 2022 RBC Capital Markets Global Healthcare Conference
    • Wednesday, May 18, 2022 at 8:00 am ET
  • UBS Global Healthcare Conference
    • Wednesday, May 25, 2022 at 8:30 AM ET

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair.  The Company has a broad pipeline of programs to address CNS and neuro-otology conditions. Its flagship program, PIPE-307, has completed a Phase 1 clinical trial in healthy volunteers and has received IND clearance from the FDA to initiate a Phase 1b/2a trial in relapsing-remitting MS patients.  For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com

« Go Back

Pipeline Therapeutics to Present at the 21st Annual Virtual Needham Healthcare Conference

SAN DIEGO, April 5, 2022 – Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today announced that company management will present at the 21st Annual Virtual Needham Healthcare Conference, taking place from April 11-14, 2022.  Carmine Stengone, Pipeline’s President and CEO, will present a company overview on April 13, 2022 at 4:30 pm ET.  Company management will also participate in one-on-one meetings with investors during the conference.

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair.  The Company has a broad pipeline of programs to address CNS and neuro-otology conditions. Its flagship program, PIPE-307, has completed a Phase 1 clinical trial in healthy volunteers and has received IND clearance from the FDA to initiate a Phase 1b/2a trial in relapsing-remitting MS patients.  For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com

« Go Back

Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1b/2a Study of PIPE-307 in Patients with Relapsing-Remitting Multiple Sclerosis 

-Company on track to begin enrolling patients in mid-2022

SAN DIEGO, March 28, 2022 – Pipeline Therapeutics, a clinical-stage biopharmaceutical  company pioneering precision neuroregeneration, today announced that the U.S. Food and Drug Administration (FDA) cleared the company to initiate its Phase 1b/2a clinical trial of PIPE-307 in patients with relapsing-remitting multiple sclerosis (RRMS).  Currently, there are no approved medicines that support myelin restoration, which represents a significant unmet medical need in the treatment of multiple sclerosis (MS). 

PIPE-307, the company’s lead program for myelin restoration, is an oral, highly selective antagonist of the muscarinic M1 receptor that is being developed for the treatment of MS.  The Company recently completed multiple Phase 1 studies of PIPE-307 in healthy volunteers, including a single and multiple-ascending dose study to evaluate safety and pharmacokinetics, and a positron emission tomography (PET) study to determine M1 receptor occupancy and clearance in the brain after a single dose of PIPE-307.  Results from the PET study demonstrate that doses tested in the Phase 1 study achieve a level of uptake in the human brain that have been associated with remyelination observed in preclinical studies. 

“FDA clearance to initiate our Phase 1b/2a clinical study of PIPE-307 is a major regulatory milestone for Pipeline, as it allows us to proceed with the evaluation of PIPE-307 in RRMS patients,” said Carmine Stengone, President and CEO of Pipeline.  “Today, approved medicines for MS patients are focused on immune modulation but do not address the fundamental MS disease pathology that leads to long-term decline in neurological function – chronic demyelination.  Our objective with PIPE-307 is to develop the first effective treatment that can restore myelin and improve outcomes for patients.”  

Stephen Huhn, M.D., Chief Medical Officer and Senior Vice President of Clinical Development of Pipeline, added, “We are excited to initiate the Phase 1b/2a study of PIPE-307 in RRMS patients, which follows on the heels of positive data from our Phase 1 studies.  The Phase 1b/2a study is designed to primarily assess the safety and tolerability of two different doses of PIPE-307 compared to placebo in RRMS patients, and to explore the use of neurophysiological, visual and radiological measures of remyelination. We remain on track to commence patient dosing in mid-2022.”

The Phase 1b/2a clinical trial of PIPE-307 will be conducted as a randomized, double-blind, placebo-controlled dose-ranging study in multiple sites across the US. The study will enroll approximately 45 patients who will undergo daily oral dosing over three months. The study is expected to start enrolling patients in mid-2022.

About PIPE-307 for Multiple Sclerosis

PIPE-307 is an oral, highly selective antagonist of the M1 muscarinic receptor commencing  clinical studies in MS patients. The Company recently completed multiple Phase 1 studies of PIPE-307 in healthy volunteers, including a single- and multiple-ascending dose study to evaluate safety and pharmacokinetics, and a PET study to determine the occupancy of brain M1 after a single dose of PIPE-307 in healthy volunteers. In these studies, PIPE-307 demonstrated linear pharmacokinetic (PK) data consistent with preclinical modeling and was generally well tolerated across all dose cohorts.  Importantly, analysis of a battery of neuropsychological measures, including tests involving psychomotor, attention, learning, and executive function, were administered in the Phase 1 study and showed no significant PK or dose related effects on cognitive function.  Results from the Phase 1 PET study demonstrated that doses tested in the Phase 1 SAD/MAD study achieve a level of uptake in the human brain that have been associated with remyelination observed in preclinical studies. 

In March 2022, the Company received clearance from the U.S. Food and Drug Administration  to proceed with a Phase 1b/2a study of PIPE-307 in RRMS patients.

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair.  The Company has a broad pipeline of programs to address CNS and neuro-otology conditions, and its flagship program, PIPE-307, has completed a Phase 1 clinical trial in healthy volunteers to support future studies in MS patients.  For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com

« Go Back

Pipeline Therapeutics to Present at Upcoming March Investor Conferences

SAN DIEGO, March 14, 2022 – Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today announced that company management will present at the following investor conferences:

  • 32nd Annual Oppenheimer Healthcare Conference
    • Tuesday, March 15th, 2022 at 1:20 pm ET
  • Stifel 2022 CNS Days
    • Monday, March 28th, 2022 at 8:45 AM ET

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair.  The Company has a broad pipeline of programs to address CNS and neuro-otology conditions, and its flagship program, PIPE-307, has completed a Phase 1 clinical trial in healthy volunteers to support future studies in MS patients.  For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com

Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com